A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06843447

Title field or adapter rule

{'original_value': 'A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:29.859888+00:00

Published At

2026-10-30T00:00:00+00:00

Record Updated At

2026-10-30

Source Retrieved At

2026-10-31T22:18:15.087634+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Ovarian Cancer Recurrent"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06843447"

protocolSection.identificationModule.officialTitle

"A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Ovarian Cancer Recurrent (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)', 'Cohort A-1 Arm 2 (R-DXd + Paclitaxel)', 'Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)', 'Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)', 'Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)', 'Cohort B-1 (R-DXd + Bevacizumab)', 'Cohort B-2 (R-DXd RP2D + Bevacizumab)', 'Cohort C-1 (R-DXd + Pembrolizumab)', 'Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)', 'Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)', 'Cohort D (R-DXd +/- Bevacizumab)', 'Cohort E-1 (R-DXd + MK-2010)'], 'description': 'IV infusion on Day 1 of every 3-week cycle.', 'name': 'Raludotatug Deruxtecan', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)', 'Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)', 'Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)', 'Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)', 'Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)', 'Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)'], 'description': 'IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.', 'name': 'Carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A-1 Arm 2 (R-DXd + Paclitaxel)', 'Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)', 'Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)', 'Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)', 'Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)'], 'description': 'IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.', 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)', 'Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)', 'Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)', 'Cohort B-1 (R-DXd + Bevacizumab)', 'Cohort B-2 (R-DXd RP2D + Bevacizumab)', 'Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)', 'Cohort D (R-DXd +/- Bevacizumab)'], 'description': 'IV infusion on Day 1 of every 3-week cycle.', 'name': 'Bevacizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)', 'Cohort A-1 Arm 2 (R-DXd + Paclitaxel)', 'Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)', 'Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)', 'Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)', 'Cohort B-1 (R-DXd + Bevacizumab)', 'Cohort B-2 (R-DXd RP2D + Bevacizumab)', 'Cohort C-1 (R-DXd + Pembrolizumab)', 'Cohort D (R-DXd +/- Bevacizumab)', 'Cohort E-1 (R-DXd + MK-2010)'], 'description': 'Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.', 'name': 'Rescue Medication', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort C-1 (R-DXd + Pembrolizumab)', 'Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)', 'Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)'], 'description': 'IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)'], 'description': 'IV injection on days 1 and 8 of each 3-week Cycle', 'name': 'Gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)'], 'description': 'IV injection administered on Day 1 of each 4-week cycle', 'name': 'Pegylated liposomal doxorubicin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort E-1 (R-DXd + MK-2010)'], 'description': 'IV infusion on Day 1 of every 3-week cycle', 'name': 'MK-2010', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Carboplatin (protocolSection.armsInterventionsModule.interventions[].name)
• Paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)
• Rescue Medication (protocolSection.armsInterventionsModule.interventions[].name)
• Gemcitabine (protocolSection.armsInterventionsModule.interventions[].name)
• Pegylated liposomal doxorubicin (protocolSection.armsInterventionsModule.interventions[].name)
• MK-2010 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.